Tezepelumab COPD Exacerbation Study

Inclusion Criteria:

1. History of moderate to very severe physician-diagnosed COPD for at least 12 monthsprior to enrolment with a post-bronchodilator FEV1/FVC<0.70 and apost-bronchodilator FEV1 ≥20% and ≤80% of predicted normal value.

2. History of at least 2 documented moderate to severe COPD exacerbations within 2 to 52 weeks prior to enrollment.

3. CAT score of ≥15 at enrollment and on day of randomization.

4. Documented treatment with triple therapy for COPD (medium or high doseICS/LABA/LAMA) throughout the year prior to enrollment. The dose of ICS should bestable for 3 months prior to enrollment.

Exclusion Criteria:

1. Clinically important pulmonary disease other than COPD, as judged by theInvestigator (including current or historic asthma diagnosis).

2. Any disorder, including, but not limited to, cardiovascular, gastrointestinal,hepatic, renal, neurological, musculoskeletal, infectious (including risk factorsfor pneumonia), endocrine, metabolic, hematological, psychiatric, or major physicalimpairment that is not stable.

3. Major surgery within 8 weeks before enrollment.

4. History of clinically significant infection requiring antibiotics or antiviralmedication within 14 days before enrollment.

5. Pregnant or breastfeeding.

6. The chest/lungs with pathology that precludes the patient's ability to complete thestudy

7. The patient has active COVID 19 infection during screening period.